Evidence map›Paper›PMID 37009936›Full record

ArticleJournal of the Egyptian National Cancer Institute2023

Molecular patterns of egyptian patients with non-squamous non-small-cell lung cancers: a clinicopathological study.

Mohamed Said Ismail, Loay Kassem, Ahmed Al-Husseiny Ali, Fatma Elzahraa Ahmed, Mohamed Shalaby, Sally Magdy

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Egyptian National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mohamed Said IsmailDepartment of Chest Diseases, Faculty of Medicine, Cairo University, Kasr Al-Ainy Hospital, Cairo, Egypt.
Loay KassemClinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Ahmed Al-Husseiny AliDepartment of Chest Diseases, Faculty of Medicine, Cairo University, Kasr Al-Ainy Hospital, Cairo, Egypt.
Fatma Elzahraa AhmedDepartment of Chest Diseases, Faculty of Medicine, Cairo University, Kasr Al-Ainy Hospital, Cairo, Egypt. Ahmedfatma516@yahoo.com.ORCID http://orcid.org/0000-0002-5037-8357
Mohamed ShalabySurgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Sally MagdyDepartment of Chest Diseases, Faculty of Medicine, Cairo University, Kasr Al-Ainy Hospital, Cairo, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDriver molecular aberrations, such as epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene rearrangement, play an important role in the oncogenesis and progression of non-squamous non-small-cell lung cancers (NSCLC). Therefore, this study aimed to detect the incidence of driver mutations among non-squamous NSCLC. PATIENTS AND

methodsThis was a retrospective-prospective cohort study on 131 patients with non-squamous NSCLC. Data on age, smoking status, chest symptoms, method of lung cancer diagnosis, molecular testing, including EGFR mutations in formalin-fixed paraffin-embedded (FFPE) tumor tissue and serum circulating tumor DNA using next-generation sequencing and ALK gene rearrangement by FFPE tumor tissue, and follow-up data regarding treatment modalities and outcomes were collected.

resultsThe median age of the patients was 57 years (range: 32-79 years). Out of 131 patients, 97 were males (74%), and 90 (68.7%) were smokers. Among 128 patients tested, 16 (12.5%) had EGFR mutations detected with either technique by formalin-fixed paraffin-embedded (FFPE) tumor tissue or/and serum circulating tumor DNA using next-generation sequencing, and 6 (4.7%) had ALK rearrangement by FFPE tumor tissue. The majority (62.6%) presented with metastatic disease. Among the 102 patients who received first-line systemic therapy, the objective response rate was 50.0% in mutated NSCLC versus 14.6% in non-mutated (p < 0.001). Among the eight mutated patients who received first-line tyrosine kinase inhibitors (TKIs), 7 patients achieved either complete response or partial response. Among the 22 mutated patients, the median overall survival was 3 months in those who did not receive targeted therapy versus not reached in those who received any type of targeted therapy (p < 0.001).

conclusionScreening patients with newly diagnosed non-squamous NSCLC for driver mutations is essential for major prognostic and therapeutic implications. Early administration of TKIs in mutated patients significantly improves disease outcomes.

Indexed as

Carcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsAdultAgedEgyptErbB ReceptorsFemaleFormaldehydeHumansMaleMiddle AgedMutationProspective StudiesProtein Kinase InhibitorsRetrospective StudiesCirculating Tumor DNAErbB ReceptorsFormaldehydeProtein Kinase InhibitorsEpidermal growth factor receptorMolecular profileNon-squamous non-small-cell lung cancerOverall survivalTargeted therapy

Identifiers

PMID37009936
PMCPMC13313946
OpenAlexW4362520668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.